Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2082354
Abstract: Abstract Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective… read more here.
Keywords: safety; secukinumab; drug survival; ixekizumab secukinumab ... See more keywords